ARCHIVES

ACS President & COO Resigns Unexpectedly; Was Seen as Contender for CEO Position

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

July 27, 2012

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

March 10, 1989

Eye Institute Director Kupfer Steps Down; UICC Begins Web-Based Surgical Pathology.

July 7, 2000

Canadian NCI Plans Review Of National Breast Screening Study

February 24, 1995

Final NIH ethics rules retain consulting ban, but limit divesture requirement to senior employees.

September 9, 2005

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

October 26, 2001